Patents by Inventor Lydie Cassard

Lydie Cassard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GP100-specific T cell receptors and related materials and methods of use
    Patent number: 9522948
    Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: December 20, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
  • GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE
    Publication number: 20140219978
    Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.
    Type: Application
    Filed: December 13, 2013
    Publication date: August 7, 2014
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
  • GP100-specific T cell receptors and related materials and methods of use
    Patent number: 8613932
    Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: December 24, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
  • GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE
    Publication number: 20120230962
    Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.
    Type: Application
    Filed: May 30, 2012
    Publication date: September 13, 2012
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
  • GP100-specific T cell receptors and related materials and methods of use
    Patent number: 8216565
    Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: July 10, 2012
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
  • GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE
    Publication number: 20100015113
    Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.
    Type: Application
    Filed: January 11, 2008
    Publication date: January 21, 2010
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg